Important: Stay covered! Are you enrolled in Apple Health (Medicaid) coverage? Make sure your address and phone number are up to date so you can stay enrolled. Report a change.
Distributing opioid overdose reversal medications (2SSB 5195)
2SSB 5195 helps to increase access to naloxone for all individuals at risk of an opioid overdose. The law requires hospital emergency departments (EDs) and many certified and licensed behavioral health settings to distribute prepackaged naloxone to individuals at risk of an opioid overdose.
On this page
Behavioral health agencies
Education materials
Please reference appendices J & K in the toolkits to locate translated versions of these educational materials.
- HCA official 2SSB 5195 harm reduction strategies and medications for opioid use disorder (MOUD).
- HCA official 2SSB 5195 overdose prevention and direction for naloxone use.
Toolkits
ED toolkit
ED appendices
- Appendix A. SB 5195 ED requirement summary
- Appendix B. Sample naloxone distribution policy
- Appendix C. Sample workflow quick sheet
- Appendix D. Sample smart phrases
- Appendix E. Sample staff training presentation
- Appendix F. Sample staff competency
- Appendix G. Sample distribution signature sheet
- Appendix H. Administrative FAQ
- Appendix I. Clinical staff FAQ
- Appendix J. Opioid overdose prevention and directions for naloxone use (trifold brochure)
- Appendix K. Patient harm reduction strategies and MOUD (trifold brochure) (Includes alternate languages)
- Appendix L. Opioid overdose prevention and directions for naloxone use (flat sheet) (EHR/AVS version)
- Appendix M. Patient harm reduction strategies and MOUD (flat sheet) (EHR/AVS version)
BHA Toolkit
BHA appendices
- Appendix A. SB 5195 BHA requirement quick sheet
- Appendix B. Administrative FAQ
- Appendix C. Frontline staff FAQ
- Appendix D. Sample workflow
- Appendix E. Sample smart phrases
- Appendix F. Sample staff training presentation
- Appendix G. Sample staff competency sheet
- Appendix H. Sample distribution signature sheet
- Appendix I. Opioid overdose prevention and directions for naloxone use (trifold brochure)
- Appendix J. Patient harm reduction strategies and MOUD (trifold brochure) (Includes alternate languages)
- Appendix K. Opioid overdose prevention and directions for naloxone use (flat sheet) (EHR/AVS version)
- Appendix L. Patient education harm reduction and MOUD (flat sheet) (ERH/AVS version)
Webinars
- HCA Lunch and Learn series for behavioral health agencies (December 8)
- HCA Lunch and Learn series for behavioral health agencies (December 15)
Contact
For training, consultation, educational materials, and implementation questions
Laura Meader, MA, LICSW
Overdose reversal medication program director
Email: laura.meader@hca.wa.gov
For billing and pharmacy questions
Email: Applehealthpharmacypolicy@hca.wa.gov